Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply
Lancet Oncol
.
2023 Mar;24(3):e104.
doi: 10.1016/S1470-2045(23)00065-7.
Authors
Stephen R D Johnston
1
,
Valérie André
2
Affiliations
1
The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK. Electronic address: Stephen.Johnston@rmh.nhs.uk.
2
Eli Lilly and Company, Indianapolis, IN, USA.
PMID:
36858725
DOI:
10.1016/S1470-2045(23)00065-7
No abstract available
Publication types
Letter
Comment
MeSH terms
Aminopyridines
Benzimidazoles
Breast Neoplasms*
Female
Humans
Immunologic Factors
Substances
abemaciclib
Aminopyridines
Benzimidazoles
Immunologic Factors